Marshall Financial Group LLC Invests $1.03 Million in DexCom, Inc. (NASDAQ:DXCM)

Marshall Financial Group LLC acquired a new stake in DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 13,235 shares of the medical device company’s stock, valued at approximately $1,029,000.

Several other institutional investors have also added to or reduced their stakes in the stock. Versant Capital Management Inc bought a new stake in DexCom in the 4th quarter valued at approximately $25,000. Riverview Trust Co raised its holdings in shares of DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after purchasing an additional 232 shares during the last quarter. RPg Family Wealth Advisory LLC bought a new stake in shares of DexCom in the third quarter worth $57,000. Covestor Ltd boosted its holdings in DexCom by 53.7% during the third quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock worth $64,000 after purchasing an additional 335 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB grew its position in DexCom by 46.7% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock valued at $65,000 after purchasing an additional 265 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

DXCM has been the topic of several analyst reports. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Raymond James dropped their target price on DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a report on Friday, October 25th. Sanford C. Bernstein raised their price target on DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. Wells Fargo & Company upped their price objective on DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Finally, Canaccord Genuity Group raised their target price on shares of DexCom from $89.00 to $99.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Five investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $99.29.

Insider Activity

In other DexCom news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the transaction, the executive vice president now owns 71,192 shares in the company, valued at $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.30% of the company’s stock.

DexCom Stock Up 1.2 %

DXCM stock opened at $88.75 on Friday. The company has a market cap of $34.67 billion, a PE ratio of 53.14, a price-to-earnings-growth ratio of 2.23 and a beta of 1.12. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The business has a 50-day simple moving average of $79.50 and a 200 day simple moving average of $77.35.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.